The SYNTAX II Trial evaluated the SYNERGY™ BP-EES Stent in a procedure-related trial involving a multitude of variables when treating patients with three-vessel disease including:

- **PHYSIOLOGY**
  - Use of physiology (FFR/iFR) in SYNTAX II demonstrated a significantly higher procedural success rate compared to SYNTAX I.
  - PCI with CTO procedural success rates jumped from 53% in SYNTAX I to 87% in SYNTAX II.
  - That represents a 64% increase in successful CTO treatment.

- **CROSSING**
  - SYNTAX II shows that physiological assessment, contemporary CTO techniques, use of the SYNERGY BP-EES Stent, and IVUS guidance demonstrate CABG-like outcomes in patients with three-vessel disease.
  - Low rates of revascularization, peri-procedural MI and acute ST suggest that SYNERGY BP-EES might help in reducing procedural related complications.

- **TREATMENT**
  - SYNTAX II demonstrates 64% improvement in CABG-like outcomes compared to SYNTAX I.

- **STENT OPTIMIZATION**
  - IVUS helps to optimize stent placement and achieve better outcomes when used as a part of contemporary PCI.

**SYNTAX II** shows that physiological assessment, contemporary CTO techniques, use of the SYNERGY BP-EES Stent, and IVUS guidance demonstrate CABG-like outcomes in patients with three-vessel disease. Boston Scientific has a minimally-invasive complete revascularization portfolio to address these needs for patients. Contact a rep today for more information.